Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study.

doi:10.1002/ijc.35060

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study.

International journal of cancer - 15 Oct 2024

Bloem Manja, van Not Olivier J, Aarts Maureen J B, van den Berkmortel Franchette W P J, Blank Christian U, Blokx Willeke A M, Boers-Sonderen Marye J, Bonenkamp Johannes J, de Groot Jan-Willem B, Haanen John B, Hospers Geke A P, Kapiteijn Ellen W, de Meza Melissa M, Piersma Djura, van Rijn Rozemarijn S, Stevense-den Boer Marion A M, van der Veldt Astrid A M, Vreugdenhil Gerard, van den Eertwegh Alfons J M, Suijkerbuijk Karijn P M, Wouters Michel W J M

Abstract excerpt

Previous studies demonstrated limited efficacy of immune checkpoint inhibitors in unresectable acral melanoma (AM); it remains unclear how this translates to the adjuvant setting. This study investigates clinical outcomes of acral compared to cutaneous melanoma (CM) patients treated with adjuvant anti-PD-1 after complete resection. All stages III-IV AM and CM patients receiving adjuvant anti-PD-1 after complete...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Immune Checkpoint Inhibitors

Share to Melanoma

Share to Netherlands

Share to Programmed Cell Death 1 Receptor

Share to Registries

Share to Skin Neoplasms

Source

Open in PubMed

Identifiers

PMID: 38922879
DOI: 10.1002/ijc.35060

Genes

BRAF
KIT
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study.PMID 38922879Read ↗

A retrospective study of anti-PD-1 combined with temozolomide adjuvant therapy for stage III resected acral melanomaSemantic proximity Read ↗

Treatment of acral and mucosal melanoma: Current and emerging targeted therapies.Semantic proximity Read ↗

Management of Acral and Mucosal Melanoma: Medical Oncology Perspective.Semantic proximity Read ↗

Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions.Semantic proximity Read ↗

Association of NRAS mutations and tertiary lymphoid structure formation with clinical outcomes of adjuvant PD-1 inhibitors for acral melanoma.Semantic proximity Read ↗

A real-world study of adjuvant anti-PD -1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations.Semantic proximity Read ↗

Identification of tumor-intrinsic drivers of immune exclusion in acral melanomaSemantic proximity Read ↗

Integrative Molecular and Clinical Profiling of Acral Melanoma Identifies LZTR1 as a Key Tumor Promoter and Therapeutic TargetSemantic proximity Read ↗

Integrative molecular and clinical profiling of acral melanoma identifies LZTR1 as a key tumor promoter and therapeutic targetSemantic proximity Read ↗

Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasisSemantic proximity Read ↗

Oncogenic signaling pathways and hallmarks of cancer in Korean patients with acral melanoma.Semantic proximity Read ↗

Optimal strategy in managing advanced melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.